Sharon Longhurst
Director/Miembro de la Junta en IDOGEN AB (PUBL) .
Perfil
Sharon Longhurst is currently an Independent Director at Idogen AB and Elicera Therapeutics AB.
Previously, she worked as the Head-Chemistry, Manufacturing & Control at Mendus AB and as the Vice President-Development at Gadeta BV from 2021 to 2023.
Dr. Longhurst holds a doctorate degree from the University of Warwick and an undergraduate degree from the University of Surrey.
Cargos activos de Sharon Longhurst
| Empresas | Cargo | Inicio |
|---|---|---|
| IDOGEN AB (PUBL) | Director/Miembro de la Junta | 12/05/2020 |
| ELICERA THERAPEUTICS AB | Director/Miembro de la Junta | 01/01/2024 |
Antiguos cargos conocidos de Sharon Longhurst.
| Empresas | Cargo | Fin |
|---|---|---|
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | 01/08/2023 |
| MENDUS AB | Corporate Officer/Principal | - |
Formación de Sharon Longhurst.
| University of Warwick | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| IDOGEN AB (PUBL) | Health Technology |
| MENDUS AB | Health Technology |
| ELICERA THERAPEUTICS AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Sharon Longhurst
